Your browser doesn't support javascript.
loading
The Metabolism of Lufotrelvir, a Prodrug Investigated for the Treatment of SARS-COV2 in Humans Following Intravenous Administration.
Cheruvu, Narayan; van Duijn, Esther; Spigt, Pieter A; Barbu, Ioana M; Toussi, Sima S; Schildknegt, Klaas; Jones, Rhys M; Obach, R Scott.
Afiliação
  • Cheruvu N; Pfizer Worldwide Research, Development and Medical, Groton, Connecticut (R.S.O., K.S.); Pfizer Worldwide Research, Development and Medical, La Jolla, California (R.M.J.); Pfizer Worldwide Research, Development and Medical, Collegeville, Pennsylvania (N.C.); Pfizer Worldwide Research, Development and
  • van Duijn E; Pfizer Worldwide Research, Development and Medical, Groton, Connecticut (R.S.O., K.S.); Pfizer Worldwide Research, Development and Medical, La Jolla, California (R.M.J.); Pfizer Worldwide Research, Development and Medical, Collegeville, Pennsylvania (N.C.); Pfizer Worldwide Research, Development and
  • Spigt PA; Pfizer Worldwide Research, Development and Medical, Groton, Connecticut (R.S.O., K.S.); Pfizer Worldwide Research, Development and Medical, La Jolla, California (R.M.J.); Pfizer Worldwide Research, Development and Medical, Collegeville, Pennsylvania (N.C.); Pfizer Worldwide Research, Development and
  • Barbu IM; Pfizer Worldwide Research, Development and Medical, Groton, Connecticut (R.S.O., K.S.); Pfizer Worldwide Research, Development and Medical, La Jolla, California (R.M.J.); Pfizer Worldwide Research, Development and Medical, Collegeville, Pennsylvania (N.C.); Pfizer Worldwide Research, Development and
  • Toussi SS; Pfizer Worldwide Research, Development and Medical, Groton, Connecticut (R.S.O., K.S.); Pfizer Worldwide Research, Development and Medical, La Jolla, California (R.M.J.); Pfizer Worldwide Research, Development and Medical, Collegeville, Pennsylvania (N.C.); Pfizer Worldwide Research, Development and
  • Schildknegt K; Pfizer Worldwide Research, Development and Medical, Groton, Connecticut (R.S.O., K.S.); Pfizer Worldwide Research, Development and Medical, La Jolla, California (R.M.J.); Pfizer Worldwide Research, Development and Medical, Collegeville, Pennsylvania (N.C.); Pfizer Worldwide Research, Development and
  • Jones RM; Pfizer Worldwide Research, Development and Medical, Groton, Connecticut (R.S.O., K.S.); Pfizer Worldwide Research, Development and Medical, La Jolla, California (R.M.J.); Pfizer Worldwide Research, Development and Medical, Collegeville, Pennsylvania (N.C.); Pfizer Worldwide Research, Development and
  • Obach RS; Pfizer Worldwide Research, Development and Medical, Groton, Connecticut (R.S.O., K.S.); Pfizer Worldwide Research, Development and Medical, La Jolla, California (R.M.J.); Pfizer Worldwide Research, Development and Medical, Collegeville, Pennsylvania (N.C.); Pfizer Worldwide Research, Development and
Drug Metab Dispos ; 51(10): 1419-1427, 2023 10.
Article em En | MEDLINE | ID: mdl-37429728
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Pró-Fármacos / COVID-19 Limite: Humans Idioma: En Revista: Drug Metab Dispos Ano de publicação: 2023 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Pró-Fármacos / COVID-19 Limite: Humans Idioma: En Revista: Drug Metab Dispos Ano de publicação: 2023 Tipo de documento: Article